Prolacta Bioscience

Prolacta Bioscience, founded with the mission to transform care for vulnerable infants, focuses on developing specialty formulations made from human milk. The company provides human milk-based nutritional products specifically designed to meet the needs of premature and critically ill infants in neonatal intensive care units (NICUs). By leveraging the biological power of human milk, Prolacta aims to improve health outcomes and reduce complications for these infants, operating primarily within the United States.

Notable figures affiliated with Prolacta Bioscience include its team of leading scientists and healthcare professionals dedicated to neonatal nutrition. The company has garnered significant investment from healthcare-focused venture capital firms. Key achievements include multiple clinical studies published in peer-reviewed journals that validate the efficacy of their products in improving infant health outcomes. Prolacta's impact is profound, as its human milk-based nutritional products have become a critical component in the care regimen for premature infants, contributing to better survival rates and reduced hospital stays.